Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy

Summary

A Phase I trial of weekly topotecan in combination with sorafenib in treatment of relapsed Small cell lung cancer (SCLC) has been commenced. In the present randomized phase 2 study, the investigators will research whether Sorafenib maintenance prolongs progression free survival (PFS) and overall survival (OS) in patients with ED-SCLC who achieved CR or PR after platinum-based induction chemotherapy.

Timeline

Start

2010-12

Primary completion

2013-04

Completion

2013-06

Outcome

Outcome not reported

Stopped (Enrollment): “low enrolling participants”

Drugs

Indications